J. Park

Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme

I. Park, Hyeon-Ok Jin, Anbok Lee, 2021, International journal of oncology.

Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge

Anbok Lee, Il-Hwan Kim, M. Haque, 2022, Cancer Immunology, Immunotherapy.

Addition of Anti-neu Antibody to Local Irradiation Can Improve Tumor-Bearing BALB/c Mouse Survival through Immune-Mediated Mechanisms

Hyunkeun Song, yang-xin fu, I. Choi, 2015, Radiation research.

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study

Sukjoong Oh, Y. Mun, C. Choi, 2023, Frontiers in Oncology.

PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.

Myung Jin Kim, S. Oh, Yong-Chul Kim, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.